Universal influenza vaccine: The holy grail?

Expert Review of Vaccines

Volumn 11, Issue 8, 2012, Pages 923-927

  Shaw, Alan R ^a  

^a VaxInnate Corporation   (United States)

Author keywords

engineered viruses; pandemic; recombinant DNA; reverse genetics

Indexed keywords

DYNAVAX; INFLUENZA VACCINE; ISCOM; PALIVIZUMAB; PROTEIN M2; UNCLASSIFIED DRUG; VAXINNATE;

AVIAN INFLUENZA; CELLULAR IMMUNITY; DRUG COST; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SEQUENCE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PUBLIC HEALTH; REVIEW; TREATMENT OUTCOME; VIROGENESIS;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DRUG INDUSTRY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; TECHNOLOGY, PHARMACEUTICAL; VIRAL MATRIX PROTEINS;

EID: 84866669366     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.73     Document Type: Review

References (24)

1. Osterholm MT, Kelley NS, Sommer A, Belongia EA. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 12(1), 36-44 (2012).
2. Lamb RA, Choppin PW. Identification of a second protein (M2) encoded by RNA segment 7 of influenza virus. Virology 112(2), 729-737 (1981).
3. Duff KC, Ashley RH. The transmembrane domain of influenza A M2 protein forms amantadine-sensitive proton channels in planar lipid bilayers. Virology 190(1), 485-489 (1992).
4. Feng J, Zhang M, Mozdzanowska K et al. Influenza A virus infection engenders a poor antibody response against the ectodomain of matrix protein 2. Virol. J. 3, 102 (2006)
5. Zebedee SL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. 62(8), 2762-2772 (1988).
6. Huleatt JW, Nakaar V, Desai P et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26(2), 201-214 (2008).
7. Neirynck S, Deroo T, Saelens X, Vanlandschoot P, Jou WM, Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 5(10), 1157-1163 (1999).
8. El Bakkouri K, Descamps F, De Filette M et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186(2), 1022-1031 (2011).
9. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibodydependent NK cell activity. J. Immunol. 172(9), 5598-5605 (2004).
10. Tissot AC, Renhofa R, Schmitz N et al. Versatile virus-like particle carrier for epitope based vaccines. PLoS ONE 5(3), e9809 (2010).
11. Fan J, Liang X, Horton MS et al. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22(23-24), 2993-3003 (2004).
12. Fu TM, Grimm KM, Citron MP et al. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 27(9), 1440-1447 (2009).
13. Bianchi E, Liang X, Ingallinella P et al. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J. Virol. 79(12), 7380-7388 (2005).
14. Turley CB, Rupp RE, Johnson C et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 29(32), 5145-5152 (2011).
15. Talbot HK, Rock MT, Johnson C et al. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS ONE 5(12), e14442 (2010).
16. Ekiert DC, Bhabha G, Elsliger MA et al. Antibody recognition of a highly conserved influenza virus epitope. Science 324(5924), 246-251 (2009).
17. Throsby M, van den Brink E, Jongeneelen M et al. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE 3(12), e3942 (2008).
18. Bommakanti G, Citron MP, Hepler RW et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc. Natl. Acad. Sci. USA 107(31), 13701-13706 (2010).
19. Graves PN, Schulman JL, Young JF, Palese P. Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of crossreactive HA2 determinants. Virology 126(1), 106-116 (1983).
20. Wang TT, Tan GS, Hai R et al. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. USA 107(44), 18979-18984 (2010).
21. Steel J, Lowen AC, Wang TT et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 1(1), pii: e00018-10 (2010).
22. Adar Y, Singer Y, Levi R et al. A universal epitope-based influenza vaccine and its efficacy against H5N1. Vaccine 27(15), 2099-2107 (2009).
23. Giles BM, Bissel SJ, Dealmeida DR, Wiley CA, Ross TM. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines. Clin. Vaccine Immunol. 19(2), 128-139 (2012).
24. Giles BM, Ross TM. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine 29(16), 3043-3054 (2011).